Dianthus Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 8, 2019 and accepted by EDGAR at Aug 8, 2019, 08:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $0 | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $0 | us-gaap:Revenues |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $13.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $24.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$19.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$35.7m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$17.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$32.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.48 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.93 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$30.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $2.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $33.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $183.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $195.4m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $9.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $15.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $179.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-19-216106. Last ingested by Listed: Nov 13, 2026, 16:49 ET. Listed shows no prices and gives no investment advice.